Høyintensitets vekselstrømstimulering som en neuromoduleringsterapi for alkoholbrukslidelse: En pilotstudie (HITACS-AUD)
Høyintensitet vekselstrømstimulering som en nevromoduleringsterapi for alkoholbrukslidelse: En pilotstudie
This one-arm pilot study aims to evaluate the preliminary clinical, behavioral, and neurophysiological effects of high-intensity transcranial alternating current stimulation (HI-tACS) in individuals with alcohol use disorder (AUD). Participants will receive HI-tACS and undergo clinical and neurophysiological assessments before and after the intervention.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Alcohol use disorder (AUD) has become a major social and public health problem. Persistent alcohol craving, impaired self-control, and abnormalities in decision-making and inhibitory control are important clinical and cognitive features of AUD. High-intensity transcranial alternating current stimulation (HI-tACS) is a non-invasive neuromodulation approach that may have potential therapeutic effects in individuals with AUD. However, its clinical and neurobiological effects in AUD remain unclear. The investigators hypothesize that HI-tACS may reduce alcohol craving and improve self-regulation and cognitive-control functions in individuals with AUD. This one-arm pilot study aims to evaluate the preliminary effects and tolerability of a 2-week course of HI-tACS, using clinical assessments together with electroencephalographic, and magnetic resonance imaging measures to explore potential changes in craving, self-control, risky decision-making, inhibitory control, and related neural activity. This study may provide preliminary clinical and mechanistic evidence for the further development of HI-tACS as a potential intervention for AUD.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Jiang Du, MD, PhD.
- Telefonnummer: +8602164906315
- E-post: dujiangdou@163.com
Studiesteder
-
-
-
Shanghai, Kina
- Rekruttering
- Shanghai Mental Health Center
-
Ta kontakt med:
- Jiang Du, MD, PhD.
- Telefonnummer: +86 021 6490 6315
- E-post: dujiangdou@163.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Education level of junior high school or above, capable of completing questionnaires and behavioral tests;
- Aged 18-60 years;
- Meet DSM-5 diagnostic criteria for Alcohol Use Disorder;
- No abnormal findings on physical examination;
- Agree to participate in follow-up assessments;
- No contraindications for MRI scanning.
Exclusion criteria:
- Have impaired intelligence (Intelligence Quotient<70);
- Prior tDCS or TMS treatment within the past 3 months;
- Contraindications for TMS therapy (e.g., intracranial metal implants, history of traumatic brain injury, skull defects, cardiac pacemakers, cardiovascular diseases, or epilepsy);
- Severe somatic diseases or major organ dysfunction;
- Psychiatric disorders per DSM-5 criteria (e.g., schizophrenia, schizoaffective disorder, intellectual disability, autism spectrum disorder, dementia, memory impairment, or other cognitive disorders).
- Psychiatric disorders per DSM-5 criteria (e.g., schizophrenia, schizoaffective disorder, intellectual disability, autism spectrum disorder, dementia, memory impairment, or other cognitive disorders).
- Diagnosis of other substance-related and addictive disorders or behavioral addictions.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: HI-tACS
A 40-minute 15mA transcranial alternating current stimulus intervention with 77.5 Hz of real stimulus is conducted twice a day (at least 3 hours apart) for a total of 10 days in the intervention group of AUD. |
A 40-minute 15mA transcranial alternating current stimulus intervention with 77.5 Hz of real stimulus is conducted twice a day (at least 3 hours apart) for a total of 10 days in the intervention group of AUD. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The change of alcohol craving
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
Alcohol craving will be measured by the alcohol craving Visual Analog Scale (VAS). The total score of VAS ranged from 0 to 10, in which higher scores mean a higher level of alcohol craving. |
Baseline, immediately after completion of the 2-week intervention
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The change of drinking urge
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
Alcohol urge will be assessed using the Alcohol Urge Questionnaire (AUQ). The total score of AUQ ranges from 8 to 56, with higher scores indicating stronger urges to consume alcohol. |
Baseline, immediately after completion of the 2-week intervention
|
|
Change of the compulsive drinking behavior
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
Compulsive drinking behavior will be measured by the short form of the Obsessive-Compulsive Drinking Scale (OCDS). The total score of OCDS ranges from 0 to 40, with higher scores reflecting greater obsessive-compulsive thoughts and behaviors related to alcohol use. |
Baseline, immediately after completion of the 2-week intervention
|
|
Side effects of the modulation
Tidsramme: Immediately after each of the 20 HI-tACS sessions during the 2-week intervention period
|
Side effects will be assessed using a standardized adverse reaction evaluation form. The presence and severity of stimulation-related adverse reactions will be recorded for each symptom. |
Immediately after each of the 20 HI-tACS sessions during the 2-week intervention period
|
|
Change of depressive symptoms.
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
Depressive symptoms will be measured using the 17-item Hamilton Depression Rating Scale (HAMD-17). The total score ranges from 0 to 52, with higher scores indicating more severe depressive symptoms. |
Baseline, immediately after completion of the 2-week intervention
|
|
Change of anxiety symptoms
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
Anxiety symptoms will be assessed using the 14-item Hamilton Anxiety Rating Scale (HAMA-14). The total score ranges from 0 to 56, where higher scores reflect greater anxiety severity. |
Baseline, immediately after completion of the 2-week intervention
|
|
Change of the self-control ability
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
Self-control ability will be measured using the Self-Control Scale (SCS). The total score ranges from 19 to 95, with higher scores of SCS indicating better self-regulation and impulse control. |
Baseline, immediately after completion of the 2-week intervention
|
|
Change of the risky decision-making performance
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
Risky decision-making will be assessed using the Balloon Analogue Risk Task (BART), with task performance and concurrent electroencephalography (EEG) measures related to risk-taking, decision-making, and outcome processing recorded. In addition, the Pig Dice Game will be administered during functional magnetic resonance imaging (fMRI) to assess risk-taking decision-making and associated task-related brain activity. Behavioral and neuroimaging measures derived from these tasks will be used to characterize changes in risk-related decision-making. |
Baseline, immediately after completion of the 2-week intervention
|
|
Change of the inhibitory control performance
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
Inhibitory control will be assessed using the Stop-Signal Task (SST), with task performance evaluated together with concurrent electroencephalography (EEG) measures related to response inhibition and inhibitory control. |
Baseline, immediately after completion of the 2-week intervention
|
|
Change of the resting state neural activity.
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
Resting-state functional magnetic resonance imaging (rsfMRI) will be used to assess intrinsic brain activity and functional connectivity. Resting-state electroencephalography (rsEEG) will be employed to assess spontaneous neural oscillatory activity. |
Baseline, immediately after completion of the 2-week intervention
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Individualized Electric Field Simulation
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
Individualized head models will be constructed using structural magnetic resonance imaging (sMRI), including T1-weighted imaging and diffusion tensor imaging (DTI). The electric field induced by HI-tACS will be simulated to characterize its spatial distribution and interindividual variability in modeled stimulation exposure. |
Baseline, immediately after completion of the 2-week intervention
|
|
Change of the molecular-level neurochemistry
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
SPICE magnetic resonance spectroscopic imaging will be used to explore changes in brain neurochemical profiles following HI-tACS. Metabolite-related signals and their spatial distributions will be assessed to characterize potential intervention-associated neurochemical alterations. Individual metabolite measurements will be analyzed separately, with their respective quantification methods and measurement units reported. |
Baseline, immediately after completion of the 2-week intervention
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- JDu-016
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .